Monocyte chemoattractant protein-1 in patients with peripheral arterial disease

Abstract

BACKGROUND: Chemokine-driven migration of inflammatory cells has been implicated in the pathogenesis of atherosclerotic conditions including peripheral arterial disease (PAD). Monocyte chemoattractant protein-1 (MCP-1) is elevated in patients with coronary artery disease and in hypertensive patients. This study therefore investigated MCP-1 in patients with PAD. METHODS: Serum MCP-1 was determined by enzyme-linked immunosorbent assay in 36 healthy, control subjects and in 19 patients with PAD. Statistical analysis utilised the Mann-Whitney test and Spearman correlation (p < 0.05). RESULTS: MCP-1 (pg/ml) was increased in patients compared with in controls (mean+/-standard error of the mean: PAD group, 748+/-60; control group, 459+/-27; p=0.0001). MCP-1 levels tended to decrease with progressing disease. From atherosclerosis risk factors, diabetes inclined to increase MCP-1 levels; hypertension had no effect. Serum MCP-1 correlated with cholesterol, triglycerides, low-density lipoprotein but not high-density lipoprotein. Conclusion: Elevation of MCP-1 in the circulation of PAD patients shown in the present pilot study implicates this CC chemokine ligand 2 in inflammatory processes contributing to PAD clinical symptomatology. Further investigations are necessary to evaluate whether MCP-1 can be used as a potential marker of peripheral arterial disease follow-up and/or prognosis.

Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells

“…Similarly, serum levels of MCP-1 are significantly elevated in patients with ischemic stroke and myocardial infarction as compared to healthy subjects [Arakelyan et al, 2005]. This association is also found in subjects with peripheral arterial disease [Petrkova et al, 2004]. Furthermore, circulating MCP-1 levels are significantly and positively associated with markers of obesity such as body mass index (BMI) and waist circumference [Kim et al, 2006].…”

Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremities

“…[33][34][35][36] Although the findings are often contradictory, 16 there is no reason to exclude the relevance of lower extremities in atherosclerosis since there are limited, but consistent and suggestive, data to the contrary. 37,38 We identified a few factors limiting the interpretation of our findings. For example, CCL2 concentration in plasma is consistently lower than in serum, and interpretation differs depending on which measurement is used.…”

Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria

“…Previous studies found that PON1 inhibits the production of CCL2 induced by oxidative stress in cultured endothelial cells, and that both PON1 and CCL2 are ubiquitously distributed in mouse tissues and, as such, implying combined systemic effects [25,26]. Clinical data suggest that plasma CCL2 concentration measurement may be an important biomarker of diseases involving inflammatory response to an increased oxidative stress [27,28]. However, there is a paucity of information on alterations in plasma CCL2 concentrations in infectious diseases.…”